The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
Capital infusion to accelerate Earendil’s R&D platform
It promises fewer injections for vision loss patients
Call it a major breakthrough for diagnostic imaging
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
Subscribe To Our Newsletter & Stay Updated
